An observational study in Cardiovascular Diseases and Diabetes Mellitus Type 2, sponsored by Marche Region Regional Health Agency. Recruiting at 2 sites in Italy. Open to participants aged 50 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Marche Region Regional Health Agency · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to test the feasibility of a new systematic screening program to allow the early detection of individuals aged 50 years at risk of type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVDs) in the resident in the province of Ascoli Piceno and without previous diagnosis, using the CUORE and FINDRISDC tools developed in the Project.
The intervention will be conducted at the premises of the Prevention Department in Ascoli Piceno and San Benedetto del Tronto, within the Local Health Authority of Ascoli Piceno (Marche Region, Italy), throughout 2026.
Eligible individuals will be invited, based on recruitment criteria, to the screening via a letter containing study information and participation instructions. Those willing to participate will book the appointment to undergo the screening in one of the two premises of the Prevention Department involved in the study (namely, San Benedetto del Tronto and Ascoli Piceno), through the regional reservation system (CUP). On the scheduled date, participants will visit the Prevention Department, where healthcare professionals (HCPs) will explain the study, obtain the informed consent, and collect data related to the CUORE and/or FINDRISC questionnaires, as well as sociodemographic information. The calculated scores will determine the 10-year risks of T2DM and major CVD events. Based on these risks, participants will be provided with tailored suggested pathways. A summary letter outlining these pathways will be delivered, and, in case of consent, results will be added to the participants' Electronic Health Record. Follow-up calls will be scheduled at 3 (T1) and 6 (T2) months to assess adherence to the suggested pathway (e.g., visit the General Practitioner (GP), lifestyle counselling) through a phone call.
Technical information:
Details about recruitment:
Persons will be enrolled in the screening program only after signing the paper-based informed consent form. The doctor will sign the consent form too, making him-/her-self available to provide further details and to solve any doubts of the participants. A signed copy of the informed consent and the information sheet will be given to each participant. Moreover, the participants will be asked to share with the doctor their telephone number, specifying that this will be used only for follow-up evaluations in relation to moderate high and very high-risk levels.
3- Details about the screening pathway:
The calculation of the scores of the FINDRISC and CUORE questionnaires will provide the 10-years risks of developing T2DM and a major CVD event, respectively. A devoted pathway will be suggested to the participants by the physician, based on the risk level of each individual, as follows:
Regarding CUORE tool, in relation to no/low risk score (\<3%), the suggested pathway foresees the strengthening of the information about healthy lifestyle, a pillar of CVDs prevention; in relation to moderate, high and very high risk scores, and in extreme values of risk factors related to blood pressure and cholesterolemia, the pathway foresees the lifestyle counselling and the referral to GP, with the suggestion to evaluate the CVD risk over time, ranging from every year (for moderate risk) to every 6 months (for high risk), in coherence with the indications of the CUORE project.
4. Legal, ethical and technical considerations:This study, and, consequently, the data collection, usage and storage procedures, will be conducted according to the principles expressed in:
The study will start only after notification and acknowledgement by the Regional Ethics Committee and the completion of the administrative requirements of the institution where the study is being conducted. No sponsorship is envisaged for the conduction of this study
5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.
This study's planned enrollment of 2,951 is above the median of 534 across 1,577 observational studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Marche Region Regional Health Agency is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The target population will be composed by the residents of Ascoli Piceno province (one of the inclusion criteria)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention will consist in a systematic screening of the participants to identify people at risk of developing T2DM (FINDRISC questionnaire) and CVDs (CUORE questionnaire, along with HbA1c).
To assess the screening adherence through coverage
This outcome will be assessed computing the percentage (%) of screening participants against invited
Time frame: This outcome will be evaluated at the end of the study (end of the year 2026), when all the eligible persons will be invited and will have had the possibility to conduct the screening evaluation
To evaluate the 10-years risk of developing Type 2 Diabetes event for each person
This outcome will be assessed evaluating the scores derived from FINDRISC tool, along with Glycated Hemoglobin (HbA1c), to determine risk of developing diabetes. FINDRISC uses: * age (score=2 for people aged 50 years) * vegetable \& fruit intake (every day=0; otherwise= 1) * history of hyperglycemia (no=0; yes=5; ) * Body Mass Index (BMI) (kg/m\^2) (from 0 to 3, as increases) * physical activity (yes=0; no=2) * medical treatment of hypertension (yes=2; no=1) * family history of diabetes (no=0; otherwise, up to 5) * waist circumference (cm) (from 0 to 4, as increases) The detection of the HbA1c will be conducted for the moderate, high and very high-risk levels, to accurately complete the risk assessment for results \>9, a cut-off level suggestive of further investigation, as per literature. Based on the final score, ranging from 0 to 26, four risk levels are defined: I- Low risk (≤9); II- Moderate risk (\>9≤15 score); III: High risk (\>15 ≤20 score); IV- Very high risk (\> 20 score).
Time frame: This outcome will be evaluated when participants will conduct the screening evaluation (T0), when the risk score will be computed.
To evaluate the 10-years risk of developing a major Cardiovascular risk event for each person
This outcome will be assessed evaluating the scores derived from CUORE tool, representing the probability of experiencing a first major cardiovascular event (myocardial infarction or stroke) in the next 10 years, based on 8 risk factors: gender, age, diabetes, smoking habit, systolic blood pressure (mmHg), total cholesterolaemia (mg/dl), High-Density Lipoprotein-cholesterolaemia (mg/dl) and anti-hypertensive treatment. The individual score is computed by the formula: 1 - \[S(t)\] \^ {EXP \[β1 × age + β2 × PAS + β3 × COL + β4 × HDL + β5 (if SMOKER) + β6 (if DIABETIC) + β7 (if TREATED with antihypertensives) - G(µ)\]}; S(t)=10-year survival evaluated at the mean value of the factors; βi= the coefficients of the risk factors; G(µ)= linear combination of the factor averages or prevalence in each cathegory by the respective coefficients βi. Based on the final score (from 0% to 100%), 3 risk levels are identified: I- Low risk: \<3%; II- Moderate risk: ≥3-\<20%; III: High risk: ≥20%.
Time frame: This outcome will be evaluated when participants will conduct the screening evaluation (T0), when the risk score will be computed.
To determine the Diabetes Mellitus Type 2 risk detection rate
This outcome will be assessed evaluating the proportion of persons with unrecognized risk of developing Diabetes Mellitus Type 2, by using the final scores from the FINDRISC tool, along with Glycated Hemoglobin, when foreseen. This detection rate is calculated as the proportion of individuals identified as having moderate, high, or very high risk of developing diabetes over the next decade, based on the FINDRISC scores.
Time frame: This outcome will be evaluated when participants will conduct the screening evaluation (T0), when the risk score will be computed.
To determine the Cardiovascular Diseases' risk detection rate
This outcome will be assessed evaluating the proportion of persons with unrecognized risk of developing a major Cardiovascula Diseases, by using the final scores from the CUORE tool, which predicts the probability of experiencing a first major cardiovascular event (such as myocardial infarction or stroke) within the next 10 years This detection rate is calculated as the proportion of individuals identified as having moderate, high, or very high risk of developing cardiovascular disease over the next decade, based on the CUORE score.
Time frame: This outcome will be evaluated when participants will conduct the screening evaluation (T0), when the risk score will be computed.
To compute the % of individuals adhering to the suggested pathway (e.g., visit to the General practitioners, or to the lifestyle counselling), according to the risk level.
This outcome will be assessed through follow-up calls. This outcome will be evaluated only for participants with moderate to high risk levels in FINDRISC and/or CUORE.
Time frame: This outcome will be evaluated at T1 and T2 (3 and 6 months respectively from the screening evaluation). Participants will be contacted in T1; if they T1 did not answer or answered not to have follow the pathway, will be contacted at T2.
To evaluate the results based on sociodemographic characteristics
This outcome will be assessed throught an ad-hoc questionnaire to collect the following information about the participants (including options "other"/ "don't know" and "I'd rather not to answer"): municipality of residence; educational level; employment status; household composition.
Time frame: This outcome will be evaluated when participants will conduct the screening evaluation (T0), when they will be asked to answer to these questions
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.
Of 583 non-industry observational studies under Cardiovascular Diseases, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 196. This study's planned 8 months is below that.
Counting every sponsor, half of 667 studies reached it within 62 months; a quarter within 24 and three quarters within 192.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Marche Region Regional Health Agency